1. Academic Validation
  2. Discovery of novel inhibitors of LEDGF/p75-IN protein-protein interactions

Discovery of novel inhibitors of LEDGF/p75-IN protein-protein interactions

  • Bioorg Med Chem. 2013 Feb 15;21(4):957-63. doi: 10.1016/j.bmc.2012.12.012.
Tino Wilson Sanchez 1 Bikash Debnath Frauke Christ Hiroyuki Otake Zeger Debyser Nouri Neamati
Affiliations

Affiliation

  • 1 Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Abstract

Human lens epithelium-derived growth factor (LEDGF)/p75 plays an important role in the HIV life cycle by stimulating integrase (IN)-led viral DNA integration into cellular chromosomes. Mechanistic studies show the majority of IN inhibitors chelate magnesium ions in the catalytic active site, a region topologically distant from the LEDGF/p75 binding site. Compounds disrupting the formation of LEDGF/p75 and IN complexes serve as a novel mechanistic approach different from current antiretroviral therapies. We previously built pharmacophore models mimicking LEDGF/p75 residues and identified four classes of LEDGF/p75-IN inhibitors. Substructure and similarity searches yielded additional LEDGF/p75-IN inhibitors containing an acylhydrazone moiety. The most potent of the acylhydrazones inhibited LEDGF/p75-IN interaction with an IC(50) value of 400nM. We explored structure-activity relationships (SAR) and identified new acylhydrazones, hydrazines, and diazenes as lead molecules for further optimization. Two lead LEDGF/p75-IN inhibitors showed Antiviral activity.

Figures